Measurement of matrix metalloproteinase 9-mediated Collagen type III degradation fragment as a marker of skin fibrosis

BMC Dermatology

Volumn 11, Issue , 2011, Pages

  Vassiliadis, Efstathios ^a,b   Veidal, Sanne S ^a,b   Barascuk, Natasha ^a,b   Mullick, Jhinuk B ^a   Clausen, Rikke E ^a,c   Larsen, Lise ^a   Simonsen, Henrik ^a   Larsen, Dorthe V ^a   Bay Jensen, Anne Christine ^a   Segovia Silvestre, Toni ^a   Leeming, Diana J ^a   Karsdal, Morten A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CO3 610; COLLAGEN TYPE 3; CREATININE; GELATINASE B; UNCLASSIFIED DRUG; BLEOMYCIN; EPITOPE; MMP9 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; MOUSE; NONHUMAN; PROTEIN DEGRADATION; SKIN FIBROSIS; STATISTICAL SIGNIFICANCE; URINE LEVEL; WESTERN BLOTTING; ANIMAL; C3H MOUSE; CHEMICALLY INDUCED DISORDER; EXTRACELLULAR MATRIX; FIBROSIS; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; SKIN DISEASE; URINE;

ANIMALS; BIOLOGICAL MARKERS; BLEOMYCIN; COLLAGEN TYPE III; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; EXTRACELLULAR MATRIX; FEMALE; FIBROSIS; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C3H; SKIN DISEASES;

EID: 79953095571     PISSN: None     EISSN: 14715945     Source Type: Journal    
DOI: 10.1186/1471-5945-11-6     Document Type: Article

References (22)

1. Barascuk N, Veidal SS, Larsen L, Larsen DV, Larsen MR, Wang J, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem 2010,
2. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 2001, 21:351-372. 10.1055/s-2001-17556, 11586465.
3. Wakatsuki T, Elson EL. Reciprocal interactions between cell and extracellular matrix during remodeling of tissue constructs. Biophysical Chemistry 2003, 100(1-3):593-605. 10.1016/S0301-4622(02)00308-3, 12646393.
4. Uitto J, Kouba D. Cytokine modulation of extracellular matrix gene expression: relevance to fibrotic skin diseases. J Dermatol Sci 2000, 24(Suppl 1):S60-S69. 10.1016/S0923-1811(00)00143-2, 11137398.
5. Arthur MJ. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2000, 279:G245-G249.
6. Friedman SL. Liver fibrosis -- from bench to bedside. J Hepatol 2003, 38(Suppl 1):S38-S53. 10.1016/S0168-8278(02)00429-4, 12591185.
7. Martinez-Hernandez A, Amenta PS. The hepatic extracellular matrix. II. Ontogenesis, regeneration and cirrhosis. Virchows Arch A Pathol Anat Histopathol 1993, 423:77-84. 10.1007/BF01606580, 8212543.
8. Jensen LT. The aminoterminal propeptide of type III procolagen, Studies on physiology and pathophysiology. Danish Medical Bulletin 1997, 44(1):70-78.
9. Ulrich D, Noah EM, Burchardt ER, Atkins D, Pallua N. Serum concentration of amino-terminal propeptide of type III procollagen (PIIINP) as a prognostic marker for skin fibrosis after scar correction in burned patients. Burns 2002, 28:766-771. 10.1016/S0305-4179(02)00193-6, 12464475.
10. Chujo S. Mechanisms of skin fibrosis and model mouse. Skin Research 2006, 5:7-15.
11. Green MC, Sweet HO, Bunker LE. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 1976, 82:493-512. 2032428, 176891.
12. Siracusa LD, Christner P, McGrath R, Mowers SD, Nelson KK, Jimenez SA. The tight skin (Tsk) mutation in the mouse, a model for human fibrotic diseases, is tightly linked to the beta 2-microglobulin (B2m) gene on chromosome 2. Genomics 1993, 17:748-751. 10.1006/geno.1993.1398, 7902327.
13. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, et al. Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999, 112:456-462. 10.1046/j.1523-1747.1999.00528.x, 10201529.
14. Yamamoto T, Takahashi Y, Takagawa S, Katayama I, Nishioka K. Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W(V) mice. J Rheumatol 1999, 26:2628-2634.
15. Yamamoto T, Kuroda M, Nishioka K. Animal model of sclerotic skin. III: Histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 2000, 292:535-541. 10.1007/s004030000183, 11194891.
16. Yamamoto T, Nishioka K. Animal model of sclerotic skin. IV: induction of dermal sclerosis by bleomycin is T cell independent. J Invest Dermatol 2001, 117:999-1001. 10.1046/j.0022-202x.2001.01509.x, 11676849.
17. Yamamoto T, Nishioka K. Animal model of sclerotic skin. V: Increased expression of alpha-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma. Clin Immunol 2002, 102:77-83. 10.1006/clim.2001.5138, 11781070.
18. Ricard-Blum S, Chossegros P, Guerret S, Trepo C, Grimaud JA, Chevallier M. The carboxy-terminal cross-linked telopeptide of type I collagen (ICTP) is a potential serum marker of ongoing liver fibrosis. Clin Chim Acta 1996, 248:187-195. 10.1016/0009-8981(95)06253-X, 8740582.
19. Stone PJ. Potential use of collagen and elastin degradation markers for monitoring liver fibrosis in schistosomiasis. Acta Trop 2000, 77:97-99. 10.1016/S0001-706X(00)00118-2, 10996125.
20. Matsushima K, Bano M, Kidwell WR, Oppenheim JJ. Interleukin 1 increases collagen type IV production by murine mammary epithelial cells. J Immunol 1985, 134:904-909.
21. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000, 21:115-137. 10.1210/er.21.2.115, 10782361.
22. Bonewald LF, Mundy GR. Role of transforming growth factor-beta in bone remodeling. Clin Orthop Relat Res 1990, 261-276.